RO-15-1788 |
RO-41-8157 |
RO-151788000 |
RO-151788 |
ROMAZICON |
MAZICON |
FLUMAZEPIL |
FLUMAZENIL |
RO-1722 |
ANEXATE |
ANEXATE® |
FLUMAZENILUM |
FLUMAZENILO |
RO15-1788 |
chembl:CHEMBL407 |
chemidplus:78755-81-4 |
pubchem.compound:3373 |
drugbank:01205 |
rxcui:4457 |
FDA Approval | 1991 |
Drug Class | small molecule |
Drug Indications | Antidotes, Benzodoazepine Overdose |
Drug Class | antidotes, benzodoazepine overdose |
Year of Approval | 1991 |
Drug Categories | benzodiazepine antagonist |
Drug Categories | compounds used in a research, industrial, or household setting |
Drug Categories | drugs that are mainly renally excreted |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | miscellaneous central nervous system agents |
allosteric modulator |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
antagonist (inhibitory) |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
positive modulator (activating) |
allosteric modulator |
antagonist (inhibitory) |
Specific Binding Site for Interaction | benzodiazepine site |
Details of the Assay for Interaction | Affinity measured using α1β3γ2 receptors. |
Specific Action of the Ligand | Antagonist |
allosteric modulator |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
Specific Binding Site for Interaction | benzodiazepine site |
allosteric modulator |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
Specific Binding Site for Interaction | benzodiazepine site |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
allosteric modulator |
Specific Binding Site for Interaction | benzodiazepine site |
Details of the Assay for Interaction | Affinity measured using α6β3γ2 receptors. |
Specific Action of the Ligand | Partial agonist |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
n/a |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
Direct Interaction | yes |
n/a |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
n/a |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel allosteric antagonist |
FLUMAZENIL | DrugBank Drug Name |
78755-81-4 | CAS Number |
Anexate | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | antidotes |
FLUMAZENIL | Primary Drug Name |
Year of Approval | 1991 |
Drug Class | antidotes, benzodoazepine overdose |
Drug Indications | Antidotes, Benzodoazepine Overdose |
Drug Class | small molecule |
FDA Approval | 1991 |
CHEMBL407 | ChEMBL Drug ID |
D0D5GD | TTD Drug ID |
FLUMAZENIL | GuideToPharmacology Ligand Name |